Get the Stockscreener App
1.60
2.44%
-0.04
After Hours:
1.59
-0.01
-0.63%
Pacific Biosciences Of California Inc stock is traded at $1.60, with a volume of 12.90M.
It is down -2.44% in the last 24 hours and down -19.60% over the past month.
Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Asia-Pacific and Europe Middle East, and Africa.
See More
Previous Close:
$1.64
Open:
$1.66
24h Volume:
12.90M
Relative Volume:
1.26
Market Cap:
$438.18M
Revenue:
$188.87M
Net Income/Loss:
$-400.38M
P/E Ratio:
-1.0667
EPS:
-1.5
Net Cash Flow:
$-260.90M
1W Performance:
+0.00%
1M Performance:
-19.60%
6M Performance:
+0.00%
1Y Performance:
-75.65%
1-Day Range:
$1.55
$1.75
1-Week Range:
$1.39
$1.75
52-Week Range:
$1.16
$6.83
Pacific Biosciences Of California Inc Stock (PACB) Company Profile
Name
Pacific Biosciences Of California Inc
Sector
Industry
Phone
650-521-8000
Address
1305 O'BRIEN DRIVE, MENLO PARK, CA
Compare PACB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PACB
Pacific Biosciences Of California Inc
|
1.60 | 438.18M | 188.87M | -400.38M | -260.90M | -1.50 |
|
ABT
Abbott Laboratories
|
128.22 | 222.39B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
105.02 | 154.78B | 15.91B | 1.79B | 1.89B | 1.21 |
|
SYK
Stryker Corp
|
396.07 | 150.99B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
90.82 | 116.46B | 33.00B | 4.29B | 5.50B | 3.27 |
|
EW
Edwards Lifesciences Corp
|
70.99 | 41.87B | 6.60B | 4.16B | 490.10M | 6.93 |
Pacific Biosciences Of California Inc Stock (PACB) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-11-24 | Downgrade | UBS | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Buy |
| Apr-22-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-18-24 | Downgrade | Goldman | Buy → Neutral |
| Dec-14-23 | Initiated | Guggenheim | Neutral |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Peer Perform |
| Nov-17-23 | Upgrade | UBS | Neutral → Buy |
| Oct-31-23 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-28-23 | Initiated | Bernstein | Outperform |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| Jun-30-23 | Initiated | Goldman | Buy |
| May-10-23 | Initiated | Barclays | Equal Weight |
| Mar-31-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Feb-02-23 | Initiated | UBS | Neutral |
| Jan-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Jan-05-23 | Initiated | Scotiabank | Sector Outperform |
| Jan-21-22 | Resumed | Cantor Fitzgerald | Overweight |
| Jan-06-22 | Resumed | Piper Sandler | Neutral |
| Oct-15-21 | Resumed | Cowen | Market Perform |
| Sep-27-21 | Initiated | Canaccord Genuity | Buy |
| Feb-11-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Nov-03-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-02-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-09-20 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-15-19 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Apr-02-19 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-19-18 | Initiated | Cowen | Outperform |
| Nov-03-17 | Downgrade | First Analysis Sec | Overweight → Equal-Weight |
| Sep-28-17 | Downgrade | CL King | Buy → Neutral |
| Nov-03-16 | Reiterated | Cantor Fitzgerald | Buy |
| Jun-27-16 | Initiated | CL King | Buy |
| Apr-15-16 | Initiated | First Analysis Sec | Overweight |
| Feb-04-16 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Jan-04-16 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-23-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Aug-27-15 | Initiated | Cantor Fitzgerald | Buy |
| Feb-04-15 | Reiterated | Maxim Group | Buy |
| Sep-26-13 | Reiterated | Maxim Group | Buy |
| Jan-14-13 | Reiterated | Maxim Group | Buy |
View All
Pacific Biosciences Of California Inc Stock (PACB) Latest News
Pacific Biosciences of California (PACB) Projected to Post Earnings on Thursday - MarketBeat
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why - MSN
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service - GlobeNewswire
Tech & Life Sciences Veteran David Ruggiero Takes Helm of PacBio's Global Sales Strategy - StockTitan
Pacific Biosciences of California (NASDAQ:PACB) investors are sitting on a loss of 86% if they invested three years ago - Yahoo Finance
PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025 - GlobeNewswire
Genomics Market to Grow by USD 5.21 Billion (2024-2028), Boosted by Rising Investments in R&D, with AI Impacting Market TrendsTechnavio - The Malaysian Reserve
Genomics Market to Grow by USD 5.21 Billion (2024-2028), Boosted by Rising Investments in R&D, with AI Driving Market TransformationTechnavio - The Malaysian Reserve
Menlo Park-based biotech company welcomes Florida exec to board - The Business Journals
Life sciences stocks fall on NIH funding concerns - MSN
Pacific Biosciences of California Appoints NeoGenomics CEO to Board of Directors -January 30, 2025 at 10:30 am EST - Marketscreener.com
Strategic Power Move: NeoGenomics CEO Joins PacBio Board to Accelerate Clinical Market Push - StockTitan
PACB (Pacific Biosciences of California) 5-Year Dividend Gr - GuruFocus.com
Pacific Biosciences of California (PACB) Stock Moves -1.18%: What You Should Know - MSN
Revolutionary DNA Tech Cracks Medical Mystery That Stumped Traditional Testing - StockTitan
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now - MSN
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $2.95 Consensus Price Target from Analysts - Defense World
Assenagon Asset Management S.A. Has $390,000 Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Defense World
JPMorgan Chase & Co. Purchases 45,957 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Defense World
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now - MSN
The Goldman Sachs Group Issues Pessimistic Forecast for Pacific Biosciences of California (NASDAQ:PACB) Stock Price - Defense World
The Goldman Sachs Group Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.75 - MarketBeat
What Analysts Are Saying About Pacific Biosciences Stock - Benzinga
PacBio Expands HiFi Sequencing Network: GIFS Becomes First Canadian Certified Provider - StockTitan
Analysts Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) PT at $2.95 - MarketBeat
Brokers Issue Forecasts for PACB FY2025 Earnings - MarketBeat
Cantor Fitzgerald Comments on PACB FY2025 Earnings - Defense World
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped - MSN
Pacific Biosciences of California (NASDAQ:PACB) Trading 8.5% HigherShould You Buy? - MarketBeat
Cantor Fitzgerald Weighs in on PACB FY2025 Earnings - MarketBeat
PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics - MSN
RNA Transcriptome Profiling Tests Market Expands at 14.5% CAGR, Surpassing US$ 37 Billion by 2034 | Fact.MR Report - GlobeNewswire Inc.
Chromosome-level genome assembly of the pine wood nematode carrier Arhopalus unicolor - Nature.com
PacBio announces preliminary Q4 revenue of $39.2M - MSN
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap DownShould You Sell? - MarketBeat
PacBio Stock May Gain Following the Collaborated Launch of GutID - MSN
PACB Stock Declines Despite Promising HiFi Sequencing Findings - Yahoo Finance
Don't Ignore The Insider Selling In Pacific Biosciences of California - Simply Wall St
Selling Pacific Biosciences of California Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St
Barclays PLC Has $1.01 Million Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB) - Defense World
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Bought by Barclays PLC - MarketBeat
PacBio reports drop in annual revenue, launches new products By Investing.com - Investing.com Canada
PacBio reports drop in annual revenue, launches new products - Investing.com India
PacBio's HiFi Sequencing Achieves 93% Success Rate in Breakthrough Rare Disease Study - StockTitan
PacBio Announces Preliminary Fourth Quarter and Full Year Revenue - Quantisnow
Pacific Biosciences Of California Inc Stock (PACB) Financials Data
Revenue
Net Income
Cash Flow
EPS
5.14%
2.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):